Health Technology · Pharmaceuticals: Major · NSE: WINDLAS · data 2026-10-09

Windlas Biotech Ltd.

Health check: Strong (6.9/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹949.2

Market cap

₹2,048 cr

P/E

30.4

P/B

—

ROE

12.2%

ROCE

13.5%

Debt / equity

0.06

Dividend yield

0.63%

1-year return

2.7%

52-week high

₹1,181.9

52-week low

₹697.4

Operating margin

7.9%

Growth

Revenue (last 12 months)	₹942 cr
Net profit (last 12 months)	₹66 cr
Sales growth, 3 years (yearly)	20.8%
Profit growth, 3 years (yearly)	16.0%

Chart patterns

Double top — breakdown (key level ₹1,050.8)

Similar companies

Sai Parenterals Limited (SAIPARENT) · Sakar Healthcare Ltd (SAKAR) · Indoco Remedies Limited (INDOCO) · Panacea Biotec Limited (PANACEABIO) · Beta Drugs Ltd. (BETA)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open WINDLAS in NSE Scanner →